Daiichi to market Nycomed imaging agent in Japan:
This article was originally published in Clinica
Daiichi is to market Nycomed Amersham's ultrasound imaging agent, NC-100100, in Japan. The product will be used in cardiology and radiology applications, including liver imaging. It will be submitted for approval in the US and Europe at the end of this year. Development in Japan is at the preclinical stage. Daiichi already markets selected Nycomed imaging agents in Japan, including the non-ionic X-ray contrast medium, Omnipaque (iohexol). Nycomed Amersham estimates the potential worldwide market for ultrasound imaging to be around $1.6 billion.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.